| Literature DB >> 30160351 |
Chenxia Hu1, Lingfei Zhao2,3, Conggao Peng1, Lanjuan Li1.
Abstract
Mesenchymal stem cells (MSCs) are broadly used in cell-based regenerative medicine because of their self-renewal and multilineage potencies in vitro and in vivo. To ensure sufficient amounts of MSCs for therapeutic purposes, cells are generally cultured in vitro for long-term expansion or specific terminal differentiation until cell transplantation. Although physiologically up-regulated reactive oxygen species (ROS) production is essential for maintenance of stem cell activities, abnormally high levels of ROS can harm MSCs both in vitro and in vivo. Overall, additional elucidation of the mechanisms by which physiological and pathological ROS are generated is necessary to better direct MSC fates and improve their therapeutic effects by controlling external ROS levels. In this review, we focus on the currently revealed ROS generation mechanisms and the regulatory routes for controlling their rates of proliferation, survival, senescence, apoptosis, and differentiation. A promising strategy in future regenerative medicine involves regulating ROS generation via various means to augment the therapeutic efficacy of MSCs, thus improving the prognosis of patients with terminal diseases.Entities:
Keywords: mesenchymal stem cell; multilineage; reactive oxygen species; regenerative medicine; self-renewal
Mesh:
Substances:
Year: 2018 PMID: 30160351 PMCID: PMC6201215 DOI: 10.1111/jcmm.13835
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Figure 1Physiologically up‐regulated ROS production is essential for MSC proliferation and differentiation
The key signalling pathways for maintaining energy metabolism and ROS homeostasis of MSCs ex vivo and in vivo
| Factor | Signalling pathway/mechanism | Effect on MSCs | Ref |
|---|---|---|---|
| Age | DNA methylation status↑ | Oxidative stress↑; mitochondrial function↓ |
|
| Long‐term culture | ROS‐induced suppression of c‐Maf↑ | Proliferative ability↓; differentiation capacity↓ |
|
| Long‐term culture | p38↑; MAPK↑; p53/p21↑ | Senescence↑ |
|
| H2O2 | p53↑; p21 ↑; p38↑; pRb↓ | Cell cycle↓; DNA damage↑ |
|
| Adipogenic differentiation | mTOR↑; NOX‐4↑; FOXO↑ | PPARγ↑ |
|
| Chondrogenic differentiation | AKT↑; ERK↑ | NOX‐2↑; NOX‐4↑ |
|
| Osteogenic differentiation | Wnt/ | ROS↑; apoptosis and necrosis rates↑ |
|
|
| Notch1↓ | ROS↓; neural stem cell‐specific proteins↑ |
|
| Particulate matter | AKT↓ | MSC proliferation↓; ROS↑ |
|
| Old rat serum | Wnt/ | MSC proliferation↓; ROS↑ |
|
| FGF‐23 | p53↑; p21↑ | Senescence↑ |
|
| TNF‐α | NF‐κB↑ | Survival rate↑; migratory capacity↑ |
|
| Atmospheric oxygen | p53↑ | Viability↓; cell growth↓ |
|
| Hypoxia | AKT↑; mTOR↑ | Proliferative capacity↑; differentiation↑ |
|
| Interleukin‐17 | MEK‐ERK↑ | MSC proliferation↑; migration↑; motility↑ |
|
| PEDF | p53↓; p16 ↓ | Cell survival rates in long‐term culture↑ |
|
| NAC | Wnt/ | Self‐renewal↑, multipotency↑; apoptosis rate↓; cell adhesion capacity↑ |
|
| Fucoidan and carvedilol | p38‐MAPK↓; JNK↓; caspase 3↓; AKT↓ | H2O2‐induced injury↓ |
|
| AGEs | ROS‐p38 mediated pathway↑ | Proliferative capacity↓; migratory capacity↓ |
|
| Apocynin | NOX↓ | Ageing process↓; osteogenesis↑ of ageing MSCs |
|
| Lycopene/Cirsium setidens | p38‐MAPK↓; JNK↓; ATM ↓; p53↓ | H2O2‐induced ROS generation↓; survival rate↑ |
|
| CoQ10 | AKT/mTOR↑ | D‐galactose‐induced MSC ageing↓; ROS↓ |
|
| Menadione and 2,3‐dimethoxy‐1,4‐naphthoquinone | ERK1/2↑; JNK1/2↑ | Migration capacity↑ |
|
| Cholesterol | ROS/p53/p21Cip1/Waf1 signalling pathway ↑ | MSC senescence↑ |
|
| High‐density lipoprotein | PI3K/Akt pathway↑ | Cell viability↑; apoptosis↓ |
|
| miR‐210 inducers | ERK1/2↑; AKT ↑; c‐Met↓ | ROS‐induced apoptosis rate↓ |
|
| Knockout of exon 4 of pNO40/PS1D in MSCs | p16↑; Rb ↑ | Ageing↑; osteogenic differentiation defect↑ |
|
Figure 2Antioxidants for MSCs contribute to the regenerative applications of MSCs